SPONSORED

This Small-Cap Telehealth Company is Working With McKesson

Carebook: a game-changing telehealth platform.

•• 4 Min
This Small-Cap Telehealth Company is Working With McKesson

**What does Carebook do?** Carebook provides digital health solutions and virtual care for pharmacies, insurance providers, employers, governments and individuals. Through its digital platform, the Carebook ecosystem model connects and empowers businesses and people on their health journey. To do so, the Company has assembled experts in the fields of health, digital engagement, engineering and design along with advisors from the pharmacy industry. Carebook has three main business verticals: i) Pharmacy ii) Virtual Care iii) Insurance <% {"name": "BoxTickerSymbol", "tickerSymbolOne": "TSX-V:CRBK", "tickerSymbolTwo": "WKN:A2QEV6"} %> **Partnership with Rexall** To develop its Pharmacy vertical, in 2018 Carebook partnered with Rexall Pharmacy Group Ltd, the operating arm of Rexall Health retail pharmacies of McKesson Canada (“McKesson”).

Rexall Health is Canada’s second largest pharmacy chain. This relationship has led to establishing the critical customer-facing expertise for the development a leading pharmacy management, loyalty and engagement product. On May 1, 2020 Carebook launched the Rexall Be Well Pharmacy app in Canada on iOS, Android and web-based. Key differentiators to Carebook’s product revolve around its ecosystem model. It harnesses digital innovation by using a Software-as-a-Service (“SaaS”) licensing model to: i) connect pharmacies, clinics and employers to patients and consumers, ii) support revenue streams from multiple features that are built in a modular fashion iii) operate at little or no costs to consumers while providing maximum value to personal health and well-being. ![Carebook 1](https://cms.dot-news.de/sites/default/files/inline-images/Carebook%201a.png) This is further coupled with the formation of powerful partnerships, such as that of Rexall Health. The product also integrates modern technological concepts such as gamification, engagement (through loyalty offers and action centers) and eventually, artificial intelligence capabilities. **Growth Opportunities** Carebook is currently building a growing pipeline of opportunities as it relates to the pharmacy, insurance, and virtual care verticals. The Company’s approach for the pharmacy and insurance verticals is similar. Its focus has been to enter each market with a Canadian anchor client and develop a tailored digital platform by vertical, which can then be rebranded and offered to similar clients in other countries. The Company’s approach to the virtual care segment relies on integration of a third-party technology.

The Company pursues growth opportunities by identifying different markets through product diversification such as patient triage, patient monitoring and back-to-work solutions. How has COVID-19 affected Carebook? With the emergence of the COVID-19 pandemic in March 2020, Carebook sought to repurpose some of its core technology platform to develop and commercialize a COVID-19 screening solution. Leveraging licensed leading AI 32 technology, Carebook developed “Carebook My Vitals | COVID-19” (“My Vitals”), a screening and triage tool that allows individuals and clinicians to get real-time vital signs measurements with their smartphone camera. <% {"name": "BoxSeenNews", "newsHeadline":" 2 Shares for the Price of 1", "link": "/news/2-shares-price-1-very-unique-gold-stock"} %> Specific vital signs are impacted when there is an infection in the lungs, which can be caused by the COVID-19 virus. During lung infection, also known as pneumonia, inflammation reduces the ability of lungs to take up oxygen. This is reflected in abnormal oxygen saturation, heart rate, and respiratory rate. For people who are experiencing COVID-19 symptoms, but who have not yet been diagnosed, vital sign measurements can help determine the best course of action, as recommended by top health professionals and organizations. For those who have been diagnosed, monitoring vital signs from home helps health professionals decide when patients can continue to stay at home or when they need go back to the hospital. \- Blood oxygen saturation levels drop. \-

Heart rate increases due to lower oxygen levels. \- Respiratory rate increases as the body tries to get more oxygen. Monitoring these three vital signs at home during the COVID-19 pandemic can help health professionals triage patients and make clinical decisions about patient care. ![Carebook 2](https://cms.dot-news.de/sites/default/files/inline-images/Carebook%202a.png) The application was designed and tested in collaboration with the Jewish General Hospital in Montreal, Canada, and is based on up-to-date COVID-19 guidelines from WHO, Government of Canada, and Government of Quebec. \*\*\*Carebook is currently seeking approval from Health Canada for the My Vitals tool.\*\*\* **Conclusion** The CRBK business model seems to be more speculative than other telehealth plays, but the company has some great backers and some interesting technology.

They claim to be able to use a phone camera and algos to measure HR, respiratory, alcohol, glucose, BP. This eliminates need for lots of wearables. Still remains to be seen. But if they do manage to succeed with their submission to Health Canada for the MyVitals app, the stock may see explosive growth. And even if that fails, they still have the virtual pharmacy vertical (Rexall partnership) which is generating $4M revenue per year right now as well as the insurance vertical. With more risk, comes reward. So if CRBK can successfully attract new clients for its virtual pharmacy platform and build upon on its insurance, and virtual care verticals as well, then we would expect the share price will get a significant rerating as it is currently trading at only 3x EV/sales compared to the peer group average of 9x. Below is a comps table comparing CRBK with the rest of the telehealth peer group. ![Carebook 3](https://cms.dot-news.de/sites/default/files/inline-images/Carebook%203a.png) <% {"name": "BoxNewsletterUnder", "companyName": "Carebook","companyTickerSymbol": "WKN:A2QEV6"} %>

Healthcare

Most Popular News

  1. SpaceX’s $8B Spectrum Deal Sends AT&T, Verizon, and T-Mobile Plummeting
  2. Is Project Vault Securing America’s Supply Chain or Squeezing It to the Breaking Point?
  3. Why Gautam Lohia Shifted from Global Consulting to Reboot a $20M Tech Micro-Cap
  4. Everyday Luxury, Unstoppable Scale: Aritzia Delivers 44% Net Revenue Growth
  5. Can Navy SEAL Leadership and Big Tech Scale Revolutionize Airborne Threat Detection?

Disclaimer


This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.